Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Osteoporosis 2Musculoskeletal Diseases 2Hyperparathyroidism 2Humoral Hypercalcemia Of Malignancy 2Endocrine System Diseases 2Neoplasms 1Bone Diseases, Endocrine 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms × parathyroid hormone-related peptide (1-36) × Clear all
NCT00580788 2016-02-11

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

University of Pittsburgh

Phase EARLY_PHASE1 Completed
14 enrolled 16 charts
Head & Neck

Humoral Hypercalcemia Of Malignancy, Endocrine System Diseases, Hyperparathyroidism, Musculoskeletal Diseases, Neoplasms, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡